This study aims to demonstrate the non-inferiority of the Equinox System compared to the iLux 2020 System for the treatment of evaporative dry eye disease resulting from meibomian gland dysfunction (MGD). The research involves approximately 120 participants enrolled across a minimum of three and up to five sites within the United States.
Study Design and Procedures
The study’s duration is expected to be six months, with participant involvement spanning approximately four weeks, including pretreatment, treatment day, two-week, and four-week follow-up visits. The investigational therapy utilizes low-level light therapy (LLLT) in conjunction with manual expression of the meibomian glands. LLLT employs gentle light to stimulate cellular function, potentially repairing damaged cells and improving healthy cell function. It may also warm natural oils in the eyelids and reduce the presence of mites near the eyelashes. These effects are intended to support overall eye health and comfort.
Treatment Protocol
Participants will be randomized to receive treatment using either the Equinox System (a red mask) or the iLux 2020 System. There is a 50% chance of receiving treatment with the Equinox System and a 50% chance of receiving treatment with the iLux 2020 System. During treatment, participants will be positioned in either the prone or supine position and will wear the red mask for 17 minutes. Protective eyewear is not required, and participants will be instructed to keep their eyes closed to ensure full application of the treatment to the upper and lower lids and the periorbital area. Immediately following the 17-minute treatment, the mask will be removed, and the meibomian glands will be manually expressed by a trained and qualified clinician.